Sera Levels of microRNA-124 in Newly Diagnosed Patients with Type 2 Diabetes Mellitus in Iraqi Population

• Published in: Journal of pioneering medical sciences 2024-02, Vol.13 (1), p.138-143
• Main Authors: Al-Lami, Huda B., ZEMNI, Ramzi, Yassin, Ammar Gany
• Format: Article
• Language: English
• ISSN: 2309-7981; 2309-7981
• DOI: 10.61091/jpms202413124

Recently, circulating microRNAs (miRNAs) have emerged as potential new biomarkers for diagnosing and prognosis a wide range of disorders. The study aimed to compare the sera levels of miRNA21 and miRNA124 among newly diagnosed patients e with type 2 diabetes mellitus (T2DM) patients with their levels in apparently healthy subjects using blood samples. The time frame for this case-control research is August 2022 through March 2023, and it took place at Al-Sadr Teaching Hospital/Madina in Masin. One hundred patients with a recent di recently patients with T2DM (50 females) and 100 control participants appeared to be healthy but were really between the ages of 5 and 70. We took 2 ml of blood from each patient and healthy person, placed it in an EDTA tube with 1 ml of Trizole as a preservative, and put the tubes in the freezer at -20 degrees Celsius until we were ready to analyze the samples. Recent studies prove the relationship between miR-124 and inflammatory processes and insulin resistance; our emphasis suggests the role miR-124 in insulin resistance in T2DM. Studies have explored the potential of miR-124 as a diagnostic biomarker for T2DM. Altered expression levels of these miRNAs have been detected in sera of newly T2DM-diagnosed patients, which promises to be a non-invasive technique for the disease. Regarding therapeutic scope, miR-124 may be used as a target for insulin sensitivity. Modulating this miRNA may have a potential therapeutic impact in managing T2DM. It is important to note that significant progress has been made in understanding the involvement of miR-124 in T2DM. New studies may provide additional knowledge on its mechanism to decrease insulin receptor resistance and beta cell function, hence, the pathophysiology of T2DM.